Cheryl Woolsey

Summary

Affiliation: Sun Health Research Institute
Country: USA

Publications

  1. ncbi D2 but not D3 receptors are elevated after 9 or 11 months chronic haloperidol treatment: influence of withdrawal period
    J N Joyce
    Thomas H Christopher Center for Parkinson s Disease Research, Sun Health Research Institute, Sun City, AZ 85351, USA
    Synapse 40:137-44. 2001
  2. ncbi Dopamine D3 receptor as a therapeutic target for antipsychotic and antiparkinsonian drugs
    J N Joyce
    Thomas H Christopher Center for Parkinson s Disease Research, Sun Health Research Institute, 10515 West Santa Fe Drive, Sun City, AZ 85351, USA
    Pharmacol Ther 90:231-59. 2001
  3. ncbi Loss of response to levodopa in Parkinson's disease and co-occurrence with dementia: role of D3 and not D2 receptors
    J N Joyce
    Thomas H Christopher Center for Parkinson s Disease Research, Sun Health Research Institute, 10515 West Santa Fe Drive, Sun City, AZ 85351, USA
    Brain Res 955:138-52. 2002
  4. ncbi Dopamine D3 receptor agonists for protection and repair in Parkinson's disease
    Jeffrey N Joyce
    TH Christopher Center for Parkinson s Disease, Sun Health Research Institute, 10515 West Santa Fe Drive, Sun City 85351, USA
    Curr Opin Pharmacol 7:100-5. 2007
  5. ncbi Dopamine D3 receptor antagonists as therapeutic agents
    Jeffrey N Joyce
    T H Christopher Center for Parkinson s Disease, Sun Health Research Institute, 10515 West Santa Fe Drive, Sun City, 85351, USA
    Drug Discov Today 10:917-25. 2005
  6. pmc Low dose pramipexole is neuroprotective in the MPTP mouse model of Parkinson's disease, and downregulates the dopamine transporter via the D3 receptor
    Jeffrey N Joyce
    Thomas H Christopher Center for Parkinson s Disease Research, Sun Health Research Institute, 10515 West Santa Fe Dr, Sun City, AZ 85352, USA
    BMC Biol 2:22. 2004
  7. ncbi Methamphetamine-induced loss of striatal dopamine innervation in BDNF heterozygote mice does not further reduce D3 receptor concentrations
    Jeffrey N Joyce
    Sun Health Research Institute Christopher Center for Parkinson s Disease Research, Sun City, Arizona 85351, USA
    Synapse 52:11-9. 2004
  8. ncbi Loss of D3 receptors in the zitter mutant rat is not reversed by L-dopa treatment
    Jeffrey N Joyce
    Thomas H Christopher Center for Parkinson s Disease Research, Sun Health Research Institute, Sun City, AZ 85351, USA
    Exp Neurol 187:178-89. 2004
  9. ncbi Involvement of dopamine D(2)/D(3) receptors and BDNF in the neuroprotective effects of S32504 and pramipexole against 1-methyl-4-phenylpyridinium in terminally differentiated SH-SY5Y cells
    Steve P Presgraves
    Thomas H Christopher Center for Parkinson s Disease Research, Sun Health Research Institute, 10515 West Santa Fe Drive, Sun City, AZ 85351, USA
    Exp Neurol 190:157-70. 2004
  10. ncbi Degeneration of dopaminergic neurons in the substantia nigra of zitter mutant rat and protection by chronic intake of Vitamin E
    Shuichi Ueda
    Department of Histology and Neurobiology, JST RISTEX, Dokkyo University School of Medicine, Mibu, Tochigi 321 0293, Japan
    Neurosci Lett 380:252-6. 2005

Research Grants

Detail Information

Publications18

  1. ncbi D2 but not D3 receptors are elevated after 9 or 11 months chronic haloperidol treatment: influence of withdrawal period
    J N Joyce
    Thomas H Christopher Center for Parkinson s Disease Research, Sun Health Research Institute, Sun City, AZ 85351, USA
    Synapse 40:137-44. 2001
    ..This suggests that an elevation in D3 receptors identified at postmortem in schizophrenics withdrawn from antipsychotics is not the result of the previous drug history [Gurevich et al. (1997) Arch Gen Psychiatry 54:225-232]...
  2. ncbi Dopamine D3 receptor as a therapeutic target for antipsychotic and antiparkinsonian drugs
    J N Joyce
    Thomas H Christopher Center for Parkinson s Disease Research, Sun Health Research Institute, 10515 West Santa Fe Drive, Sun City, AZ 85351, USA
    Pharmacol Ther 90:231-59. 2001
    ..It may also be that D3 receptor agonists can provide neuroprotective effects in PD and can modify clinical symptoms that D2 receptor-preferring agonists cannot provide...
  3. ncbi Loss of response to levodopa in Parkinson's disease and co-occurrence with dementia: role of D3 and not D2 receptors
    J N Joyce
    Thomas H Christopher Center for Parkinson s Disease Research, Sun Health Research Institute, 10515 West Santa Fe Drive, Sun City, AZ 85351, USA
    Brain Res 955:138-52. 2002
    ..Thus, loss of dopamine D(3) receptors may be a more important contributing factor to a loss of response to dopaminergic drugs than changes in the D(2) receptor...
  4. ncbi Dopamine D3 receptor agonists for protection and repair in Parkinson's disease
    Jeffrey N Joyce
    TH Christopher Center for Parkinson s Disease, Sun Health Research Institute, 10515 West Santa Fe Drive, Sun City 85351, USA
    Curr Opin Pharmacol 7:100-5. 2007
    ..Of particular interest, dopamine D3 receptors contribute to the beneficial influence of dopaminergic agonists for the protection and restoration of dopaminergic pathways in Parkinson's disease...
  5. ncbi Dopamine D3 receptor antagonists as therapeutic agents
    Jeffrey N Joyce
    T H Christopher Center for Parkinson s Disease, Sun Health Research Institute, 10515 West Santa Fe Drive, Sun City, 85351, USA
    Drug Discov Today 10:917-25. 2005
    ..In addition, D(3) receptors could be involved in behavioral sensitization and the potential application of D(3) receptor antagonists in the treatment of drug abuse is undergoing intensive experimental investigation...
  6. pmc Low dose pramipexole is neuroprotective in the MPTP mouse model of Parkinson's disease, and downregulates the dopamine transporter via the D3 receptor
    Jeffrey N Joyce
    Thomas H Christopher Center for Parkinson s Disease Research, Sun Health Research Institute, 10515 West Santa Fe Dr, Sun City, AZ 85352, USA
    BMC Biol 2:22. 2004
    ..We also determined whether subchronic treatment with pramipexole regulates dopamine transporter function, thereby reducing intracellular transport of the active metabolite of MPTP, 1-methyl-4-phenylpyridinium (MPP+)...
  7. ncbi Methamphetamine-induced loss of striatal dopamine innervation in BDNF heterozygote mice does not further reduce D3 receptor concentrations
    Jeffrey N Joyce
    Sun Health Research Institute Christopher Center for Parkinson s Disease Research, Sun City, Arizona 85351, USA
    Synapse 52:11-9. 2004
    ..In addition, the reduction of D(3) receptor expression is associated with a decreased neurotoxic response to methamphetamine in BDNF +/- mice...
  8. ncbi Loss of D3 receptors in the zitter mutant rat is not reversed by L-dopa treatment
    Jeffrey N Joyce
    Thomas H Christopher Center for Parkinson s Disease Research, Sun Health Research Institute, Sun City, AZ 85351, USA
    Exp Neurol 187:178-89. 2004
    ..Thus, unlike in 6-hydroxydopamine-treated rats, in Zi/Zi rats administered L-dopa does not reverse the loss of BDNF mRNA or lead to an elevation of D(3) receptor number...
  9. ncbi Involvement of dopamine D(2)/D(3) receptors and BDNF in the neuroprotective effects of S32504 and pramipexole against 1-methyl-4-phenylpyridinium in terminally differentiated SH-SY5Y cells
    Steve P Presgraves
    Thomas H Christopher Center for Parkinson s Disease Research, Sun Health Research Institute, 10515 West Santa Fe Drive, Sun City, AZ 85351, USA
    Exp Neurol 190:157-70. 2004
    ..Their actions also reflect downstream recruitment of BDNF and via a PK3-AKT pathway...
  10. ncbi Degeneration of dopaminergic neurons in the substantia nigra of zitter mutant rat and protection by chronic intake of Vitamin E
    Shuichi Ueda
    Department of Histology and Neurobiology, JST RISTEX, Dokkyo University School of Medicine, Mibu, Tochigi 321 0293, Japan
    Neurosci Lett 380:252-6. 2005
    ..Thus, the zitter rat may represent a good model for studying the dopaminergic cell death by superoxide species...
  11. ncbi Terminally differentiated SH-SY5Y cells provide a model system for studying neuroprotective effects of dopamine agonists
    Steven P Presgraves
    Molecular and Cellular Biology Graduate Group, Arizona State University, Tempe, AZ, USA
    Neurotox Res 5:579-98. 2004
    ..Further characterization of the neuroprotective effects of DA agonists in this model system can provide unique information about DA receptor dependent and independent mechanisms of neuroprotection...
  12. ncbi Increases in dopamine D3 receptor binding in rats receiving a cocaine challenge at various time points after cocaine self-administration: implications for cocaine-seeking behavior
    Janet L Neisewander
    Department of Psychology, Arizona State University, Tempe, AZ 85287 1104, USA
    Neuropsychopharmacology 29:1479-87. 2004
    ..Collectively, the findings suggest that regulatory responses of D3 receptors may be functionally related to changes in propensity for cocaine-seeking behavior...
  13. ncbi Substantia nigra Marinesco bodies are associated with decreased striatal expression of dopaminergic markers
    Thomas G Beach
    Sun Health Research Institute, Sun City, Arizona 85372, USA
    J Neuropathol Exp Neurol 63:329-37. 2004
    ..Further studies are needed to ascertain the molecular basis of Marinesco body formation; preliminary studies indicate that proteasome dysfunction can lead to similar abnormalities in cultured cells...
  14. ncbi S32504, a novel naphtoxazine agonist at dopamine D3/D2 receptors: II. Actions in rodent, primate, and cellular models of antiparkinsonian activity in comparison to ropinirole
    Mark J Millan
    Institut de Recherches Servier, Centre de Recherches de Croissy, Psychopharmacology Department, Paris, France
    J Pharmacol Exp Ther 309:921-35. 2004
    ..Although activation of D(2) receptors is crucial to the motor actions of S32504, engagement of D(3) receptors contributes to its neuroprotective properties...
  15. ncbi Behavioral effects of dopamine agonists and antagonists in MPTP-lesioned D3 receptor knockout mice
    Alex V Yarkov
    Thomas H Christopher Center for Parkinson s Disease Research, Sun Health Research Institute, 10515 West Santa Fe Drive, Sun City, AZ 85351, USA
    Pharmacol Biochem Behav 76:551-62. 2003
    ..This may be more apparent in MPTP-lesioned partially DA denervated mice...
  16. ncbi Neuroprotective effects of the novel D3/D2 receptor agonist and antiparkinson agent, S32504, in vitro against 1-methyl-4-phenylpyridinium (MPP+) and in vivo against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a comparison to ropinirole
    Jeffrey N Joyce
    Thomas H Christopher Center for Parkinson s Disease Research, Sun Health Research Institute, 852622, Sun City, AZ, USA
    Exp Neurol 184:393-407. 2003
    ..The underlying mechanisms and therapeutic pertinence of these actions will be of interest to further evaluate in view of its potent actions in behavioral models of antiparkinson activity...
  17. ncbi Motor impairment in normal aging, clinically possible Parkinson's disease, and clinically probable Parkinson's disease: longitudinal evaluation of a cohort of prospective brain donors
    Charles H Adler
    Parkinson s Disease and Movement Disorders Center, Mayo Clinic Scottsdale, 13400 East Shea Boulevard, Scottsdale, AZ 85259, USA
    Parkinsonism Relat Disord 9:103-10. 2002
    ..This study underscores the importance of longitudinal antemortem testing of prospective brain donors as well as the potential value of quantitative motor testing...
  18. pmc Upregulation of Arc mRNA expression in the prefrontal cortex following cue-induced reinstatement of extinguished cocaine-seeking behavior
    Arturo R Zavala
    Department of Psychology, Arizona State University, Tempe, Arizona 85287 1104, USA
    Synapse 62:421-31. 2008
    ....

Research Grants4

  1. MESOLIMBIC DOPAMINE D3 RECEPTOR AND PARKINSON'S DISEASE
    Jeffrey Joyce; Fiscal Year: 2002
    ..This will further elucidate the pathology of DAergic substrates of specific clinical symptoms in PD and provide a broader basis for developing effective treatment strategies based on specific DA receptors. ..